港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

抗疫概念

890.999

+0.6250.07%

漲家數：5

跌家數：11

平家數：2

市盈率：- -

高：909.667

開：890.747

低：887.715

收：890.374

資料載入中...

總覽新聞資訊

醫藥週報：康方生物PD1/VEGF雙抗研發成果，點燃全球雙抗熱情【東吳醫藥朱國廣團隊】

国广有话说

康哲藥業分拆德鎂醫藥上市，後者連續三年虧損

【首藥控股：擬不超7.87億元建設新藥研發與產業化基地項目】首藥控股4月27日晚間公告，公司擬以自有及自籌資金不超過7.87億元，在亦莊新城國際醫藥創新公園自主建設新的“首藥控股新藥研發與產業化基地”項目，並與北京經濟技術開發區管委會簽署《經濟發展合作協議》。該合作協議生效後，公司將按照招拍掛供應程序取得項目宗地，建設包括研發中心、質控中心、臨牀試驗中心、銷售中心及生產基地在內的公司新總部，建設期3年。

【汽車行業週報】監管規範智駕用語，車企上海車展避談智駕

汽车之家资讯

“BYD SHENZHEN”今日啓運，搭載超7000台比亞迪新能源車前往巴西

比亚迪官微

比亞迪旗下全球最大汽車運輸船啓航首航前往巴西

观点新媒体

復星醫藥(02196)完成發行2025年度第一期中期票據(科創票據)

【四環醫藥(00460.HK)：渼顏空間自主研發的聚乳酸面部填充劑(童顏針)獲得國家藥監局上市批准】四環醫藥(00460.HK)發佈公告，集團旗下渼顏空間生物科技(吉林)有限公司自主研發的聚乳酸面部填充劑(該產品)正式獲得中國國家藥品監督管理局批准的第三類醫療器械註冊證，用以糾正中重度鼻唇溝皺紋。標誌着四環醫藥在再生醫美領域的又一重大突破，進一步鞏固了集團在高端醫美材料市場的技術領先地位。

王傳福大手筆，比亞迪分紅上百億

四環醫藥：渼顏空間自主研發的童顏針獲得國家藥監局上市批准

君實生物(01877.HK)特瑞普利單抗新適應症上市申請獲批

阿斯达克财经

石藥集團(01093.HK)新藥SYH2068注射液獲准開展臨牀試驗

阿斯达克财经

比亞迪2025Q1業績符合預期，單車盈利趨勢良好

比亞迪閃耀2025世界汽車大獎：海鷗榮獲“世界城市車”李柯問鼎“世界汽車年度人物”

德鎂醫藥擬分拆赴港上市，連虧三年，銷售費用高企

深圳商报·读创

新華製藥：4月27日召開業績説明會，投資者參與

证星公司调研

君實生物，2025沒有退路

江蘇威凱爾醫藥科技股份有限公司藥品申請臨牀試驗默示許可獲受理

和徑醫藥科技（上海）有限公司藥品申請臨牀試驗默示許可獲受理

2025年1-2月乘用車出口：新興市場持續領跑，新能源車企全球佈局成效顯著

盖世汽车每日速递

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1515/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":890.99915,"timestamp":1745568501389,"preClose":890.3739,"halted":0,"volume":435899656,"delay":0,"changeRate":0.000702,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":0.625244,"latestTime":"04-25 16:00:00","open":890.74744,"high":909.6669,"low":887.7149,"amount":3129554435,"amplitude":0.024655,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745803800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745544600000,1745553600000],[1745557200000,1745568000000]],"pbRate":1.60334,"peRate":21.395071,"turnoverRate":0.005773,"increases":5,"decrements":12,"flats":1,"marketCap":614989925952,"floatMarketCap":505251641024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":909.6669,"amplitude":0.024655,"preClose":890.3739,"low":887.7149,"pbRate":"1.60334","latestPrice":890.99915,"volume":435899656,"delay":0,"open":890.74744,"prevYearClose":787.97723,"prevWeekClose":849.427,"prevMonthClose":870.015,"prevQuarterClose":870.015,"fiveDayClose":838.217,"twentyDayClose":875.086,"sixtyDayClose":761.95,"secType":"PLATE","market":"HK","turnoverRate":0.005773,"peRate":21.395071,"marketCap":614989925952,"floatMarketCap":505251641024,"timestamp":1745568501389,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":5,"down":11,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530528584","title":"醫藥週報：康方生物PD1/VEGF雙抗研發成果，點燃全球雙抗熱情【東吳醫藥朱國廣團隊】","url":"https://stock-news.laohu8.com/highlight/detail?id=2530528584","media":"国广有话说","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530528584?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 23:47","pubTimestamp":1745768855,"startTime":"0","endTime":"0","summary":"PD-1/VEGF双抗确定性进一步增强，关注IO双抗赛道投资机会。4月25日，康方生物依沃西单抗注射液新适应症获NMPA批准上市，单药用于PD-L1阳性的EGFR阴性和ALKzc的局部晚期或转移性非小细胞肺癌的一线治疗。ASCO大会第二代双抗IO集体披露数据，板块将迎来强数据催化。今年ASCO会议康方生物、三生制药、华博生物将披露PD-1/VEGF双抗数据，此外信达、泽璟也将披露各自的第2代IO数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428010826a469624c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428010826a469624c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1720050803.USD","LU0348783233.USD","LU0348784397.USD","LU0417516571.SGD","09939","IE00BPRC5H50.USD","09926","IE00B543WZ88.USD","BK1574","BK1161","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","BK1515"],"gpt_icon":1},{"id":"2530453738","title":"康哲藥業分拆德鎂醫藥上市，後者連續三年虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453738","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453738?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 21:38","pubTimestamp":1745761125,"startTime":"0","endTime":"0","summary":"港股上市公司康哲药业近日发布公告，将附属公司德镁医药股份分拆并于联交所主板独立上市。德镁医药主要负责康哲药业在国内的皮肤健康业务，最近三年均处亏损状态。目前，德镁医药已向联交所递交申请，康哲药业表示，分拆预计将通过由康哲药业以实物方式向股东分派其持有的所有德镁医药股份的方式实施。德镁医药为康哲药业附属公司，德镁医药90.8%权益由康哲药业实益拥有。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504273390338112.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504273390338112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BYV24P56.USD","BK1574","SG9999015945.SGD","09939","00867","IE00BMCWC346.EUR","SG9999015978.USD","BK1515","SG9999004220.SGD","LU2488822045.USD","SG9999015952.SGD","BK1161","BK1191","SG9999015986.USD","BK1593"],"gpt_icon":0},{"id":"2530453653","title":"【首藥控股：擬不超7.87億元建設新藥研發與產業化基地項目】首藥控股4月27日晚間公告，公司擬以自有及自籌資金不超過7.87億元，在亦莊新城國際醫藥創新公園自主建設新的“首藥控股新藥研發與產業化基地”項目，並與北京經濟技術開發區管委會簽署《經濟發展合作協議》。該合作協議生效後，公司將按照招拍掛供應程序取得項目宗地，建設包括研發中心、質控中心、臨牀試驗中心、銷售中心及生產基地在內的公司新總部，建設期3年。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453653","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453653?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 21:24","pubTimestamp":1745760272,"startTime":"0","endTime":"0","summary":"首药控股4月27日晚间公告，公司拟以自有及自筹资金不超过7.87亿元，在亦庄新城国际医药创新公园自主建设新的“首药控股新药研发与产业化基地”项目，并与北京经济技术开发区管委会签署《经济发展合作协议》。该合作协议生效后，公司将按照招拍挂供应程序取得项目宗地，建设包括研发中心、质控中心、临床试验中心、销售中心及生产基地在内的公司新总部，建设期3年。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/27212449931207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1161","09939","BK1515","BK1583","BK1576","688197","BK1574","03347","159938","BK0239"],"gpt_icon":0},{"id":"2530458962","title":"【汽車行業週報】監管規範智駕用語，車企上海車展避談智駕","url":"https://stock-news.laohu8.com/highlight/detail?id=2530458962","media":"汽车之家资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530458962?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 20:49","pubTimestamp":1745758140,"startTime":"0","endTime":"0","summary":"正巧上海车展，各大车企争分夺秒修改上海车展的“智驾” 宣传物料。传统车企，比亚迪百亿分红：拟10送转20派39.74元。出行市场，曹操出行拟赴港上市，试图用定制化造车加智能驾驶破局。比亚迪1季度销量同比59.8%高增，利润同比翻倍公司3月新能源汽车销量为37.74万辆，同比增长23.1%，今年一季度累计新能源汽车销量为100.08万辆，同比增长59.81%，继续保持高速增长势头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042720542394e4b85e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042720542394e4b85e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","HYDD.SI","LU0509642566.USD","LU0865486749.SGD","BYDDY","LU0823414478.USD","BK1504","LU1242518931.SGD","LU1023057109.AUD","LU0244354667.USD","BK1522","LU0417516738.SGD","LU0543330566.HKD","SG9999006514.SGD","01211","LU0359201612.USD","LU0320764599.SGD","LU0211977185.USD","LU0214875030.USD","LU2249611893.SGD","LU2399975544.HKD","LU2476274308.USD","002594","LU0359202008.SGD","LU2153592121.USD","BK1607","LU0516422366.SGD","LU1242518857.USD","BK1515","LU0175139822.USD","81211","LU0348735423.USD","LU0449515922.USD","LU1720050803.USD","LU0348827113.USD","SG9999014674.SGD","LU0593848301.USD","SG9999015952.SGD","LU0819121731.USD","LU0164872284.USD","LU1861219969.SGD","LU2778985437.USD","LU0540923850.HKD","LU1861214812.USD","BK1589","LU0449509016.USD","LU0708995583.HKD","LU0289961442.SGD","BK1582"],"gpt_icon":1},{"id":"2530458744","title":"“BYD SHENZHEN”今日啓運，搭載超7000台比亞迪新能源車前往巴西","url":"https://stock-news.laohu8.com/highlight/detail?id=2530458744","media":"比亚迪官微","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530458744?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 20:27","pubTimestamp":1745756820,"startTime":"0","endTime":"0","summary":"2025年4月27日，全球最大汽车运输船“BYD SHENZHEN”号在江苏太仓装载超7000台比亚迪新能源车开启首次远洋航行驶往巴西。4月22日，“BYD SHENZHEN”号在江苏仪征成功举行了隆重的交付仪式。仪式上的砍缆环节象征着“BYD SHENZHEN”号开启璀璨航程，也标志着比亚迪全球化布局进入全新阶段。此次“BYD SHENZHEN”号首航的目的地为巴西，彰显了比亚迪对推动巴西可持续发展的坚定决心，还进一步巩固了比亚迪在全球新能源汽车领域的领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-04-27/doc-ineurmit7377768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2476274308.USD","LU0289960550.SGD","LU0516423091.SGD","BK0196","BK1580","LU0289739343.SGD","LU2097828805.USD","LU1781817850.SGD","LU1880383440.USD","EVS.SI","LU0327786744.USD","002594","LU0463099449.HKD","81211","LU0588546209.SGD","LU1868837722.USD","LU0823426480.USD","LU1820825898.SGD","BK1515","LU1064130708.USD","LU1720050803.USD","SG9999015978.USD","BK0070","BYDDY","BK1540","LU0633140727.USD","LU1808992512.USD","LU2360107325.USD","LU1961090484.USD","LU2495084118.USD","LU1969619763.USD","LU0572944931.SGD","LU2328871848.SGD","LU0175139822.USD","HYDD.SI","161028","LU0683595622.HKD","01211","LU0084288322.USD","BK1522","BK1589","LU2097828631.EUR","SG9999002463.SGD","BK1594","LU0359201612.USD","399417","LU0143863198.USD","LU0054450605.USD"],"gpt_icon":1},{"id":"2530921437","title":"比亞迪旗下全球最大汽車運輸船啓航 首航前往巴西","url":"https://stock-news.laohu8.com/highlight/detail?id=2530921437","media":"观点新媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530921437?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 20:01","pubTimestamp":1745755271,"startTime":"0","endTime":"0","summary":"观点网讯：4月27日，全球最大汽车运输船“BYD SHENZHEN”号在江苏太仓装载超过7000台比亚迪新能源车，首次远洋航行前往巴西，标志着比亚迪国际化战略进程中的又一重要里程碑。“BYD SHENZHEN”号的成功交付和首航，是比亚迪全球化布局进入全新阶段的象征。该船由比亚迪自主运营，拥有9200个标准装载车位，相当于一次能将停满20个足球场的汽车运往全球各地，大幅提升新能源车的全球运输效率。免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427200425a4692a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427200425a4692a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0084288322.USD","LU0175139822.USD","LU0348805143.USD","LU2097828474.EUR","LU0348766576.USD","LU1880383366.USD","LU0244354667.USD","LU1794554557.SGD","BK1594","LU0865486749.SGD","LU0307460666.USD","LU0588546209.SGD","LU1880383440.USD","LU2778985437.USD","SG9999002463.SGD","LU1868838027.USD","LU1251922891.USD","LU0823426308.USD","SG9999014674.SGD","LU1961090484.USD","BK1504","SG9999015945.SGD","BK1515","LU1770034418.SGD","SG9999015952.SGD","LU0229945570.USD","LU0449509016.USD","LU0359202008.SGD","002594","HYDD.SI","BK1540","LU0348825331.USD","LU2249611893.SGD","LU2360107325.USD","LU0979878070.USD","81211","LU1861214812.USD","LU0214875030.USD","LU0143863784.USD","LU0823426480.USD","SG9999015986.USD","LU1242518857.USD","LU0052750758.USD","LU0588545490.SGD","LU0561508036.HKD","LU0269904917.USD","LU0516422366.SGD","01211","BYDDY"],"gpt_icon":0},{"id":"2530431472","title":"復星醫藥(02196)完成發行2025年度第一期中期票據(科創票據)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530431472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530431472?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:58","pubTimestamp":1745751538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，公司近日于通知书项下注册额度内完成2025年度第一期中期票据(科创票据)(本期中期票据)的发行。中期票据简称：25复星医药MTN001(科创票据)，实际发行总额人民币5亿元，期限2年。发行利率3.10%，起息日期2025年4月25日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0239","159982","BK0028","BK0175","BK0096","600196","BK0183","BK0187","BK0188","BK0196","02196","BK1191","BK0060","BK1593","BK0012"],"gpt_icon":0},{"id":"2530243190","title":"【四環醫藥(00460.HK)：渼顏空間自主研發的聚乳酸面部填充劑(童顏針)獲得國家藥監局上市批准】四環醫藥(00460.HK)發佈公告，集團旗下渼顏空間生物科技(吉林)有限公司自主研發的聚乳酸面部填充劑(該產品)正式獲得中國國家藥品監督管理局批准的第三類醫療器械註冊證，用以糾正中重度鼻唇溝皺紋。標誌着四環醫藥在再生醫美領域的又一重大突破，進一步鞏固了集團在高端醫美材料市場的技術領先地位。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530243190","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530243190?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:57","pubTimestamp":1745751459,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK)发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂(该产品)正式获得中国国家药品监督管理局批准的第三类医疗器械注册证，用以纠正中重度鼻唇沟皱纹。标志着四环医药在再生医美领域的又一重大突破，进一步巩固了集团在高端医美材料市场的技术领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/27185749930234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1191","BK1593","159883","09996","BK1222","09997","000973.SH","BK1515","BK1574","159837","BK1600","00460","BK1100"],"gpt_icon":0},{"id":"2530437929","title":"王傳福大手筆，比亞迪分紅上百億","url":"https://stock-news.laohu8.com/highlight/detail?id=2530437929","media":"新行情","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530437929?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:54","pubTimestamp":1745751262,"startTime":"0","endTime":"0","summary":"不难看出，比亚迪此举直接将股价降低到了百元级别，无异于降低了投资者参与的门槛。与此同时，比亚迪的现金分红总额连续三年增长，叠加送转股方案，综合回报率可达历史新高。比亚迪大手笔的底气追根溯源，比亚迪的底气与其业绩高增长和资金储备离不开关系。在业绩方面，比亚迪的营收与利润实现了双突破。在现金储备方面，比亚迪的经营活动净现金流285亿元，现金储备达1549亿元。其次，比亚迪对全产业链进行了把控。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427200821a6ca65bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427200821a6ca65bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0979878070.USD","SG9999015945.SGD","LU2249611893.SGD","LU0449509016.USD","LU1251922891.USD","BK1515","SG9999014674.SGD","LU1961090484.USD","LU1770034418.SGD","81211","LU1242518857.USD","LU0269904917.USD","LU1861214812.USD","SG9999015986.USD","LU0214875030.USD","BK1594","002594","HYDD.SI","LU0229945570.USD","LU0348766576.USD","BK1540","LU1880383366.USD","LU0588546209.SGD","LU0865486749.SGD","LU0588545490.SGD","LU0143863784.USD","LU1880383440.USD","LU0823426480.USD","LU0244354667.USD","LU1868838027.USD","LU2778985437.USD","BYDDY","LU0348805143.USD","LU0307460666.USD","LU0561508036.HKD","LU2360107325.USD","SG9999015952.SGD","SG9999002463.SGD","LU0359202008.SGD","LU0516422366.SGD","01211","LU0084288322.USD","BK1504","LU2097828474.EUR","LU0175139822.USD","LU0823426308.USD","LU0052750758.USD","LU1794554557.SGD","LU0348825331.USD"],"gpt_icon":1},{"id":"2530395634","title":"四環醫藥：渼顏空間自主研發的童顏針獲得國家藥監局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530395634","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530395634?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:26","pubTimestamp":1745749560,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨四环医药宣布，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂正式获得中国国家药品监督管理局批准的第三类医疗器械注册证，用以纠正中重度鼻唇沟皱纹。渼颜空间自主研发的“童颜针”，采用独特的专利技术，使其含有的左旋聚乳酸微球具有形态更规则、粒径分布更均一、品质稳定性更高的特点，显着提高产品的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427182830a4691469&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427182830a4691469&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1600","00460","BK1191"],"gpt_icon":0},{"id":"2530433028","title":"君實生物(01877.HK)特瑞普利單抗新適應症上市申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2530433028","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530433028?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 17:49","pubTimestamp":1745747340,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布，特瑞普利单抗(商品名：拓益)用于不可切除或转移性黑色素瘤的一线治疗的新适应症上市申请获国家药品监督管理局批准。这是特瑞普利单抗在内地获批的第12项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132907304_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132907304_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436134/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01877","BK0239","BK1161","BK1583","BK1515","688180"],"gpt_icon":0},{"id":"2530330844","title":"石藥集團(01093.HK)新藥SYH2068注射液獲准開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530330844","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530330844?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 17:47","pubTimestamp":1745747220,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布，集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA)获中国国家药品监督管理局批准，可以在内地开展临床试验。该产品适用于治疗高脂蛋白血症，通过优化序列和化学修饰的策略来实现更持久的基因沉默效果，具有预防动脉粥样硬化性心血管疾病的潜力。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436132/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE0008369823.USD","IE0008368742.USD","IE00B5MMRT66.SGD","BK1515","LU1152091168.USD","LU1226288253.USD","IE00B031HY20.USD","LU1226287529.USD","01093","LU0067412154.USD","LU1152091754.HKD","03347","IE00B543WZ88.USD","LU1960683339.HKD","LU0501845795.SGD","LU0072913022.USD","BK1141","BK1521","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1583","IE00BZ08YT58.USD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU0326950275.SGD","BK1576","LU0880133367.SGD","LU1008478684.HKD","LU1226287875.USD","LU1807302812.USD","LU0140636845.USD","LU1226288170.HKD","LU1951186391.HKD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2530438172","title":"比亞迪2025Q1業績符合預期，單車盈利趨勢良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2530438172","media":"招商证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530438172?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 17:15","pubTimestamp":1745745338,"startTime":"0","endTime":"0","summary":"二、销量与市场地位比亚迪在2025年第一季度继续巩固其全球新能源汽车市场的领先地位，销量达100.08万辆，同比增长59.8%，成为全球纯电动汽车季度销量冠军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427172826a6ca3dfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427172826a6ca3dfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1720050803.USD","BK1515","SG9999015978.USD","LU1868838027.USD","LU0540923850.HKD","LU0543330566.HKD","IE00BD6J9T35.USD","LU0214875030.USD","BYDDY","LU0254981946.USD","LU2097828631.EUR","BK1540","LU1794554557.SGD","LU0588545904.SGD","LU0856984785.SGD","LU2360107325.USD","002594","LU2476274308.USD","LU2348774022.SGD","LU0348825331.USD","BK1504","LU0052750758.USD","LU0819121731.USD","LU0143863784.USD","LU1880383366.USD","BK1610","LU1719994722.HKD","LU0327786744.USD","81211","LU0588545730.USD","LU0865486749.SGD","LU2097828805.USD","01211","LU2778985437.USD","LU1242518931.SGD","LU0511384066.AUD","LU1961090484.USD","LU0509642566.USD","LU0516422366.SGD","LU0516423091.SGD","LU1880383440.USD","HYDD.SI","LU0274383008.USD","LU0359202008.SGD","LU1188198961.HKD","LU0244354667.USD","LU0516422952.EUR","LU0449509016.USD","BK1589"],"gpt_icon":1},{"id":"2530879654","title":"比亞迪閃耀2025世界汽車大獎：海鷗榮獲“世界城市車”李柯問鼎“世界汽車年度人物”","url":"https://stock-news.laohu8.com/highlight/detail?id=2530879654","media":"雷锋网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530879654?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 16:39","pubTimestamp":1745743140,"startTime":"0","endTime":"0","summary":"比亚迪海鸥凭借创新设计及城市通勤性能，从全球12款车型中脱颖而出，首度为中国品牌捧回被誉为“汽车界奥斯卡”的“世界城市车”奖杯。近年来，比亚迪以硬核科技实力屡获国际认可：2024年海豚入围“世界城市车”三强，海豹跻身“世界年度车”三强，使其成为首个同时入围两大奖项的中国车企。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427164437974727ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427164437974727ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0084288322.USD","LU0828238088.HKD","LU0348767384.USD","LU0505663152.USD","LU0348766576.USD","BK1509","BK1539","LU0516422440.USD","SG9999006597.SGD","LU0244354667.USD","LU0315178854.USD","BK1594","LU0307460666.USD","LU1188198961.HKD","SG9999014674.SGD","LU0289961442.SGD","SG9999015945.SGD","BK1515","LU0211977185.USD","LU0588545730.USD","SG9999015952.SGD","LU0359202008.SGD","LU0540923850.HKD","002594","LU0572944931.SGD","HYDD.SI","LU0516423174.USD","LU1861219969.SGD","LU0348825331.USD","LU0274383008.USD","BK1607","81211","LU0417516738.SGD","LU0214875030.USD","LU0143863784.USD","LU0516423091.SGD","LU2348774022.SGD","LU1242518857.USD","SG9999015986.USD","BK1589","LU2476274308.USD","LU0823414478.USD","LU2399975544.HKD","BK1610","LU0269904917.USD","LU1242518931.SGD","01211","SG9999015978.USD","BYDDY"],"gpt_icon":1},{"id":"2530648768","title":"德鎂醫藥擬分拆赴港上市，連虧三年，銷售費用高企","url":"https://stock-news.laohu8.com/highlight/detail?id=2530648768","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530648768?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 16:28","pubTimestamp":1745742526,"startTime":"0","endTime":"0","summary":"港股康哲药业（00867）近日公告，拟分拆旗下控股子公司德镁医药于香港联交所独立上市，华泰国际为其独家保荐人。值得注意的是，康哲药业已经连续两年营收、净利双双下降，而德镁医药更是连续三年出现亏损，而且亏损额有进一步扩大的趋势。康哲药业近期发布2024财年年报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504273390137362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2530748448","title":"新華製藥：4月27日召開業績説明會，投資者參與","url":"https://stock-news.laohu8.com/highlight/detail?id=2530748448","media":"证星公司调研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530748448?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 15:32","pubTimestamp":1745739135,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年4月27日新华制药发布公告称公司于2025年4月27日召开业绩说明会。重视投资者意见反馈，及时披露信息。答:新华制药召开2024年度业绩说明会的目的是便于投资者更加深入地了解公司经营业绩、发展战略等情况，与投资者沟通交流，并广泛听取意见和建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042715331497471a12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042715331497471a12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","06978","00719","BK1574","BK1191"],"gpt_icon":0},{"id":"2530848317","title":"君實生物，2025沒有退路","url":"https://stock-news.laohu8.com/highlight/detail?id=2530848317","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530848317?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:27","pubTimestamp":1745731621,"startTime":"0","endTime":"0","summary":"康方生物的伊努西单抗、君实生物的昂戈瑞西单抗、恒瑞医药的瑞卡西单抗，这三款PCSK9药物应该都在紧张筹备2025国谈了。2025年医保谈判，将非常考验这三款产品的谈判技巧。2023年8月，信达的托莱西单抗上市，恰好赶上同期上市的诺华英克司兰钠降价相逼。信达只能死保2025年的医保资格，才能有实力和安进、赛诺菲一战。还好，托莱西单抗进医保后销量还不错，有机构预计2027年收入可达约5000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427132845a468ca6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427132845a468ca6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","BK1515","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2530835874","title":"江蘇威凱爾醫藥科技股份有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835874","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835874?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，江苏威凯尔医药科技股份有限公司联合申请药品“VC005片”，获得临床试验默示许可，受理号CXHL2500200。江苏威凯尔医药科技股份有限公司，成立于2010年，位于南京市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，江苏威凯尔医药科技股份有限公司共对外投资了3家企业，参与招投标项目19次，知识产权方面有商标信息12条，专利信息47条，此外企业还拥有行政许可74个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1161","09939","BK1515","BK1583","BK1576","BK1574","03347","159938"],"gpt_icon":0},{"id":"2530483315","title":"和徑醫藥科技（上海）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530483315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530483315?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，和径医药科技（上海）有限公司联合申请药品“HJ-002-03片”，获得临床试验默示许可，受理号CXHB2500069。和径医药科技（上海）有限公司，成立于2017年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，和径医药科技（上海）有限公司专利信息14条，此外企业还拥有行政许可3个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09939","BK1515","BK1141","BK1574","03347","BK1576","159938","BK1583","BK1161"],"gpt_icon":0},{"id":"2530100284","title":"2025年1-2月乘用車出口：新興市場持續領跑，新能源車企全球佈局成效顯著","url":"https://stock-news.laohu8.com/highlight/detail?id=2530100284","media":"盖世汽车每日速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530100284?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 12:07","pubTimestamp":1745726828,"startTime":"0","endTime":"0","summary":"2025年开局，中国乘用车出口延续全球化扩张的强劲势头，以多元化市场布局与差异化竞争策略书写新篇章。2025年1-2月中国乘用车出口东南亚市场榜单显示，比亚迪汽车以20,707辆的累计出口量强势领跑，同比激增357.1%，其新能源车型在东南亚市场的渗透力显著提升，成为推动中国车企出海的核心力量。2025年1-2月中国乘用车出口北美的市场呈现出明显的两极分化态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427122030a468bdf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427122030a468bdf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516738.SGD","SG9999015952.SGD","LU1023057109.AUD","81211","LU0979878070.USD","SG9999014674.SGD","LU0823414478.USD","BK1515","LU2778985437.USD","SG9999015986.USD","LU0084288322.USD","LU0164872284.USD","LU2249611893.SGD","LU1242518857.USD","HYDD.SI","SG9999006597.SGD","BK1594","BK1522","LU0175139822.USD","LU0449515922.USD","LU1861214812.USD","BYDDY","LU0543330566.HKD","BK1149","LU0211977185.USD","SG9999015945.SGD","LU0588546209.SGD","002594","LU2097828631.EUR","LU2097828557.USD","BK1589","LU1242518931.SGD","SG9999015978.USD","LU0143863198.USD","01211","SG9999001226.SGD","LU0509642566.USD","SG9999002463.SGD","SG9999006514.SGD","LU0348767384.USD","LU0516422440.USD","LU1861219969.SGD","LU2097828474.EUR","LU0143863784.USD","600104","BK1504","LU0823426480.USD","LU0359201612.USD","LU0828238088.HKD","BK1539"],"gpt_icon":1}],"pageSize":20,"totalPage":23,"pageCount":1,"totalSize":458,"code":"91000000","status":"200"}]}}